|
Authorities in China have approved a drug for the treatment of Alzheimer's disease, the first new medicine with the potential to treat the cognitive disorder in 17 years. 中国有关部门已批准一种治疗阿尔茨海默症的药物，这是17年来首个可能对这种认知障碍有治疗效果的新药。 The seaweed-based drug, called Oligomannate, can be used for the treatment of mild to moderate Alzheimer's, according to a statement from China's drug safety agency. 中国药品安全监督管理局发表的一份声明显示，这个被称为甘露特钠胶囊的海藻类药物可以用于治疗轻度至中度的阿尔茨海默症。 The approval is conditional however, meaning that while it can go on sale during additional clinical trials, it will be strictly monitored and could be withdrawn should any safety issues arise. 然而，批准是有条件的，虽然它可以在额外的临床试验期间上市销售，但将受到严格监督，如果出现任何安全问题，可能会被撤回。 In September, the team behind the new drug, led by Geng Meiyu at the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences, said they were inspired to look into seaweed due to the relatively low incidence of Alzheimer's among people who consume it regularly. 这一新药的研究团队由中国科学院上海药物研究所的耿美玉带领，他们在九月份说受到启发研究海藻是因为经常食用海藻的人中阿尔茨海默症的发病率相对较低。 | 
